![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
OPTIMIZE Trial: Noninferiority of Twice-daily Telaprevir Versus Administration Every 8 Hours inTreatment-naïve, Genotype 1 HCV-infected Patients
|
|
|
Reported by Jules Levin
AASLD Boston 2012 Nov 10-14
Maria Buti,1 Kosh Agarwal,2 Yves Horsmans,3 William Sievert,4 Ewa Janczewska,5 Stefan Zeuzem,6 Lisa Nyberg,7 Robert S Brown Jr,8 Christophe Hezode,9 Mario Rizzetto,10 Raymundo Parana,11 Sandra De Meyer,12 Donghan Luo,13 James Witek13
1Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain; 2Kings College Hospital, London, UK; 3Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; 4Monash Medical Centre and Monash University, Melbourne, Australia; 5Outpatients Clinic for Hepatology, Myslowice, Poland; 6Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 7Kaiser Permanente, San Diego, CA, USA; 8Columbia University College of Physicians and Surgeons, New York, NY, USA; 9Hôpital Henri Mondor, Creteil, France; 10University of Torino, Torino, Italy; 11University Hospital of Bahia, Bahia, Brazil; 12Janssen Infectious Diseases BVBA, Beerse, Belgium; 13Janssen Research & Development LLC, Titusville, NJ, USA
![AASLD1.gif](../images/111312/111312-17/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-17/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-17/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-17/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-17/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-17/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-17/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-17/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-17/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-17/AASLD10.gif)
![AASLD11.gif](../images/111312/111312-17/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|